Celgene is set for an exit having invested $17m in small molecule cancer drug developer Nurix Therapeutics five years ago.

UCSF has unveiled Nine Square Therapeutics with $50m in series A capital from founding investor Apple Tree Partners.

The ultrasound therapeutics developer, a University of Oxford spinout, has raised series B2 funding in the run-up to clinical testing of its cancer drug delivery platform.

Novo and Sanofi are among the investors that could exit the mineralisation disease therapy developer, which has filed to raise up to $86.3m.

Pfizer Ventures joined Mission’s other existing investors to push the mitochondria-focused drug developer’s lifetime funding to approximately $143m.

University of Tübingen’s immuno-oncology spinout Immatics has undertaken a reverse merger with special purpose acquisition company Arya Sciences to list in the US.

Celebrity Kim Kardashian West’s beauty brand raised $200m at a $1bn valuation from beauty brand Coty.

The genetic testing services provider has added a Samsung-led second close to a $23m first tranche that included a range of corporate investors.

Amit Kakar will supervise a Singapore office that will spearhead the pharmaceutical company's corporate venturing investments across Asia.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.